Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
BMS-986168 · 1 trial · 1 indication
To evaluate the safety and tolerability of a single intravenous (IV) infusion of BMS-986168 in healthy subjects.
| Arm | Type | Description |
|---|---|---|
| Single Ascending dose cohorts | EXPERIMENTAL | Single ascending dose escalation, safety, tolerability, PK, PD and immunogenicity study of BMS-986168 administered by an intravenous infusion in healthy subjects. |
| Placebo | PLACEBO_COMPARATOR | BMS-986168 Placebo |
| Name | Type | Description |
|---|---|---|
| BMS-986168 | DRUG | - |
| BMS-986168 Placebo | DRUG | - |
Inclusion Criteria: * Healthy male and female subjects, who have no clinically significant deviation from normal in medical history, physical examination, ECGs and clinical laboratory determinations. * Body Mass Index (BMI) of 18.5-30 kg/m\^2, inclusive. BMI=weight (kg)/\[height(m)\]\^2. * Males an...
BMS-986168 is an investigational small molecule being developed for the treatment of tauopathies, a group of neurodegenerative diseases characterized by abnormal tau protein accumulation. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
BMS-986168 is being developed by Biogen Inc. (NASDAQ: BIIB). The company is conducting clinical trials to evaluate the safety and tolerability of this investigational therapy for tauopathies.
BMS-986168 is in Phase 1 clinical development. A single ascending dose study in healthy subjects has been completed, but the drug remains investigational and has not received regulatory approval for any indication.
BMS-986168 has one completed Phase 1 trial, NCT02294851, a randomized, double-blind, placebo-controlled, single ascending dose study of intravenously administered BMS-986168 in healthy subjects. The trial enrolled 65 participants in the United States.
BMS-986168 is not FDA approved. It is an investigational drug in Phase 1 clinical development for tauopathies. The completed trial was a healthy volunteer study, and further clinical development would be required before any regulatory submission.